Cipla Ltd

Cipla has allotted 23,282 fully paid-up equity shares of Rs 2 each, pursuant to exercise of employee stock options under the Employee Stock Option Scheme 2013-A of the Company. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs 1,61,52,80,804 comprising of 80,76,40,402 equity shares of face value Rs 2 each.Powered by Capital Market - Live

Cipla's formulation is an AB-rated therapeutic equivalent of Abraxane and is indicated for the treatment of metastatic breast cancer, advanced or metastatic non-small cell lung cancer (NSCLC), and metastatic pancreatic cancer. The product is expected to be launched in the United States of America during the first half of fiscal year 2025'26, it added. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets. The pharma major's consolidated net profit jumped 48.73% to Rs 1,570.51 crore in Q3 FY25 as against Rs 1,055.90 crore reported in Q3 FY24. Total revenue from operations grew by 7.10% year on year (YoY) to Rs 7,072.97 crore in the quarter ended 31 December 2024.Powered by Capital Market - Live

Cipla has received final approval from the United States Food and Drug Administration (USFDA) for the Abbreviated New Drug Application (ANDA) submitted for Paclitaxel Protein-bound Particles for Injectable Suspension (albumin-bound), 100 mg/vial, Single-Dose Vial (Protein-bound Paclitaxel) on 10 April 2025. Cipla's Protein-bound Paclitaxel is an AB-rated generic therapeutic equivalent version of Bristol Myers Squibb's Abraxane' for Injectable Suspension 100 mg/vial. Protein-bound Paclitaxel is indicated for the treatment of metastatic breast cancer, locally advanced or metastatic non-small cell lung cancer ('NSCLC') and metastatic adenocarcinoma of the pancreas. The product is expected to be launched in H1 FY 2025-26 in the United States of America.Powered by Capital Market - Live

Cipla will hold a meeting of the Board of Directors of the Company on 13 May 2025.Powered by Capital Market - Live

Cipla has classified its current Good Manufacturing Practices (cGMP) inspection of the company's manufacturing facility in Virgonagar, Bengaluru, conducted between 7 - 13 November 2024, as Voluntary Action Indicated (VAI). Powered by Capital Market - Live

Cipla will invest approx. ZAR 900 million in equity share capital of Cipla Medpro South Africa Proprietary Limited, a wholly-owned subsidiary of the Company in South Africa (CMSA). CMSA, is a wholly owned subsidiary of Cipla, and is the holding company for the group operations in South Africa. The group is involved in the manufacturing, marketing, and supply of pharmaceutical products. The investment will be utilised to reduce inter-group debt and improve the capital structure of CMSA and its subsidiaries. Powered by Capital Market - Live

Cipla Ltd gained for a third straight session today. The stock is quoting at Rs 1456.1, up 2.26% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.42% on the day, quoting at 23261.2. The Sensex is at 76748.82, up 0.28%. Cipla Ltd has slipped around 4.77% in last one month. Meanwhile, Nifty Pharma index of which Cipla Ltd is a constituent, has slipped around 8.79% in last one month and is currently quoting at 21163.9, up 0.9% on the day. The volume in the stock stood at 10.82 lakh shares today, compared to the daily average of 14.63 lakh shares in last one month. The benchmark January futures contract for the stock is quoting at Rs 1462.15, up 2.87% on the day. Cipla Ltd is up 7.78% in last one year as compared to a 7.07% spurt in NIFTY and a 19.04% spurt in the Nifty Pharma index.The PE of the stock is 24.71 based on TTM earnings ending December 24.Powered by Capital Market - Live

Net profit of Cipla rose 48.74% to Rs 1570.51 crore in the quarter ended December 2024 as against Rs 1055.90 crore during the previous quarter ended December 2023. Sales rose 7.01% to Rs 6961.60 crore in the quarter ended December 2024 as against Rs 6505.66 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales6961.606505.66 7 OPM %28.5726.86 - PBDT2195.891902.06 15 PBT1916.091668.63 15 NP1570.511055.90 49 Powered by Capital Market - Live

Total revenue from operations grew by 7.10% year on year (YoY) to Rs 7,072.97 crore in the quarter ended 31 December 2024. Profit before tax was at Rs 1,916.09 crore in the December quarter of FY25, up 30% from Rs 1,473.81 crore recorded in Q3 FY24. EBITDA in Q3 FY25 stood at Rs 1,989 crore, registering a growth of 15.7% on YoY basis. EBITDA margin improved to 28.1% as compared to 26.3% recorded in the corresponding quarter previous year. In Q2 FY25, One India Business grew at a healthy 10% YoY. The branded prescription business continued to outpace the market growth in key therapies, Trade Generics is back on a growth trajectory, and Anchor brands of CHL continued to grow bigger. The North America business delivered quarterly revenue of $226 million, supported by traction in differentiated assets that helped to overcome the Lanreotide supply shortfall. The business also received various generic drug approvals, including phenytonadione injectable 1 mg/0.5 ml, esomeprazole granules 2.5 mg/5 ml, and potassium phosphate injection USP. One Africa recorded a strong growth of 9% YoY in USD terms. In the private market, secondary growth was at a healthy 8.8% versus the market growth of 2.0%. The deep market focus strategy in emerging markets and Europe has laid a strong foundation, resulting in a 20% growth in USD terms. This growth was driven by an uptick in both the DTM and B2B categories, while overall margins remained sustained. Research and development (R&D) investments stood at Rs 360 crore, representing 5.1% of sales. This was driven by product filings and ongoing development efforts. The company reported a net cash position of Rs 8,947 crore. The debt primarily consists of lease liabilities and working capital requirements. Umang Vohra, MD and Global CEO at Cipla, said, 'I am pleased to share that we continue to make considerable progress across our focused markets. In Q3 FY25, we delivered growth across all our various geographies, despite a supply challenge in the U.S. We recorded a revenue growth of 8% over last year with the highest-ever EBITDA margin of 28.1%, driven by mix and other operational efficiencies. Our One-India business grew at a healthy 10% YoY. Key therapies in the branded prescription business continued to outpace the market growth, Trade Generics business growth trajectory is back on track, and Anchor brands in the consumer health business maintained leadership positions. With a positive traction in our differentiated assets, the US business posted revenue of $226 million. In South Africa, we recorded a solid growth of 21% YoY in local currency terms. Emerging markets and Europe delivered substantial revenue growth of 20% YoY on the back of a deep market focus strategy. Going ahead, the focus will be on growing our key markets, further building our flagship brands, investing in future pipelines, as well as focusing on resolutions on the regulatory front.'. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolios in our home markets of India, South Africa, North America, and key regulated and emerging markets. Powered by Capital Market - Live

In a regulatory filing, the pharmaceutical major informed that the US FDA had conducted an inspection at the manufacturing facility of Medispray Laboratories (Medispray) located in Kundaim, Goa, from 14th to 20th of January 2025. On conclusion of the inspection, Medispray received one observation in Form 483. The company will work closely with the USFDA and remains committed to address these observations comprehensively within stipulated time, Cipla said in a statement. Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. The scrip lost 0.52% to end at Rs 1438.35 on the BSE today. Powered by Capital Market - Live